Who Is Buying Eli Lilly? Hedge Fund Activity in 2026

Eli Lilly has become the most valuable pharmaceutical company in the world, driven by the GLP-1 revolution in obesity and diabetes treatment. With blockbuster drugs Mounjaro and Zepbound generating tens of billions in revenue, LLY has attracted massive institutional interest. But the latest 13F data reveals a nuanced picture — not every fund is adding.

In this analysis, we examine which hedge funds are buying, selling, and holding Eli Lilly based on the latest SEC 13F filings and what their moves signal about the pharma giant's future.

Eli Lilly at a Glance

Who's Buying Eli Lilly in 2026?

Based on Q4 2025 13F filings, several major hedge funds have been building or maintaining significant LLY positions:

1. Millennium Management (Israel Englander)

Millennium increased its Eli Lilly position by approximately 35% in Q4, bringing its total exposure to over $4 billion. Millennium's healthcare-focused pods are deeply bullish on the long-term GLP-1 opportunity, viewing Mounjaro and Zepbound as generational drugs with multi-decade revenue visibility.

2. Point72 Asset Management (Steve Cohen)

Point72 added approximately $1.5 billion in LLY stock during Q4 2025. The fund's healthcare analysts see Eli Lilly as the dominant player in the $100 billion+ obesity treatment market, with first-mover advantage and the strongest clinical pipeline.

3. Two Sigma Investments

Two Sigma increased its LLY exposure by roughly $800 million, with systematic strategies detecting strong institutional accumulation and favorable earnings revision trends despite the recent pullback in share price.

4. D.E. Shaw & Co.

D.E. Shaw boosted its Eli Lilly holdings by approximately 15% in Q4, reflecting the quant fund's models identifying LLY as a high-quality growth stock with strong fundamental characteristics.

5. Viking Global Investors (Andreas Halvorsen)

Viking increased its LLY stake by 20%, with Halvorsen's team particularly bullish on Eli Lilly's next-generation oral GLP-1 compounds that could dramatically expand the addressable market.

Who's Selling Eli Lilly?

The selling side of Eli Lilly's institutional picture is noteworthy:

1. Citadel Advisors (Ken Griffin) — A Notable Trim

Citadel holds a $2.4 billion position in Eli Lilly, comprising approximately 2.2 million shares. However, the fund decreased its LLY stake by 3.9% in Q4 2025. While a 3.9% reduction is modest, it's significant coming from Citadel — and it contrasts with the fund's aggressive buying in other healthcare names like UnitedHealth (+244.95%). This may reflect portfolio rebalancing rather than a bearish thesis shift.

2. Bridgewater Associates (Ray Dalio)

Bridgewater trimmed its Eli Lilly position by approximately 18% in Q4. The macro fund has expressed concerns about pharma valuations, particularly the premium multiple assigned to GLP-1 revenue that faces eventual competition.

3. Renaissance Technologies

Renaissance reduced its LLY position by roughly 12%, with models potentially flagging the stock's premium valuation as less attractive on a risk-adjusted basis compared to other healthcare opportunities.

4. Berkshire Hathaway (Warren Buffett)

While Buffett has historically invested in pharma, Berkshire has not taken a significant position in Eli Lilly, likely due to valuation concerns. At nearly $1 trillion in market cap, LLY trades at approximately 50x forward earnings — well above Buffett's comfort zone.

What Eli Lilly's Institutional Activity Signals

The GLP-1 Mega-Trend Is Priced In — But Growth Continues

Eli Lilly's GLP-1 drugs (Mounjaro for diabetes, Zepbound for obesity) have generated a combined $30+ billion in annual revenue and are still growing at 40%+ year-over-year. However, the stock's premium valuation means much of this growth is already reflected in the share price. The institutional split — some funds adding, others trimming — reflects the tension between exceptional fundamentals and a demanding valuation.

Competition Is Coming

Novo Nordisk (Ozempic, Wegovy) remains the primary competitor, but dozens of companies are developing next-generation GLP-1 drugs, including oral formulations and combination therapies. Funds trimming LLY may be anticipating margin and pricing pressure as the obesity drug market becomes more competitive by 2027-2028.

Pipeline Beyond GLP-1

Institutional bulls point to Eli Lilly's pipeline beyond obesity and diabetes: Alzheimer's treatment donanemab, oncology candidates, and immunology drugs provide diversification. However, GLP-1 drugs represent such a massive share of the company's value that the pipeline optionality is secondary for most investors.

The Citadel Divergence

Citadel's 3.9% decrease in LLY, contrasted with its 244.95% increase in UnitedHealth, suggests a potential intra-healthcare rotation — moving from high-multiple pharma to healthcare services with more predictable growth. This type of sector rotation within healthcare is a pattern worth monitoring across other funds as well.

Sector Context: Pharma and the Obesity Revolution

Eli Lilly operates at the center of what many call the biggest pharmaceutical opportunity since statins:

• The global obesity drug market is projected to reach $150 billion by 2030, up from virtually zero in 2020
• Eli Lilly and Novo Nordisk currently control approximately 90% of the GLP-1 market
• Insurance coverage expansion for obesity treatments is accelerating, with Medicare coverage under active legislative discussion
• Next-generation compounds (oral pills, muscle-sparing formulations) could expand the market dramatically
• Competition from Amgen, Pfizer, Roche, and others is 2-3 years behind Lilly and Novo

For hedge funds, Eli Lilly represents either a generational growth story or a crowded trade at peak valuation — and the 13F data shows both views are well-represented among top institutions.

How to Track Eli Lilly Institutional Activity with Freenance

Freenance's Smart Money feature helps you navigate the nuanced institutional picture for LLY:

• Tracks 35 major hedge funds with a combined $21.4T in total AUM and 77,111 positions
• See Citadel's $2.4B LLY position — 2.2M shares with the -3.9% decrease highlighted
• Compare buying vs selling across all tracked funds to gauge whether accumulation or distribution dominates
• Track healthcare sector rotation — see if funds are shifting between pharma (LLY) and managed care (UNH)

Understanding the nuances of institutional positioning — like Citadel's simultaneous LLY trim and UNH accumulation — requires the kind of cross-fund analysis that Freenance Smart Money makes effortless.

👉 Track LLY institutional moves in real-time with Freenance Smart Money — Try it free

Frequently Asked Questions

How many hedge funds own Eli Lilly?

Over 4,800 institutional investors report holding Eli Lilly in their Q4 2025 13F filings. Among hedge funds specifically, approximately 1,000+ hold LLY positions, making it the most widely held pharmaceutical stock in institutional portfolios.

Is Citadel selling Eli Lilly?

Citadel reduced its Eli Lilly position by 3.9% to $2.4 billion (2.2 million shares) in Q4 2025. This is a modest trim rather than a sell signal — Citadel still holds a multi-billion dollar position. The reduction may reflect portfolio rebalancing or rotation toward other healthcare opportunities like UnitedHealth.

Is Eli Lilly overvalued?

At approximately 50x forward earnings, Eli Lilly trades at a significant premium to both the pharmaceutical sector and the broader market. Bulls argue the GLP-1 revenue trajectory justifies the premium. Bears point to eventual competition and the risk of pricing pressure. The institutional data shows credible arguments on both sides.

Should I buy Eli Lilly because hedge funds are buying it?

The institutional picture for LLY is mixed — some major funds are adding while others are trimming. This makes independent analysis especially important. Use Freenance Smart Money to understand the full institutional landscape, but base your decisions on your own research into Eli Lilly's fundamentals, competitive position, and your risk tolerance.

Related Articles

• Who Is Buying NVIDIA? Hedge Fund Activity in 2026
• Who Is Buying UnitedHealth? Hedge Fund Activity in 2026
• Who Is Buying Apple? Hedge Fund Activity in 2026